Breakthrough in Gene Therapy Stabilizes Neuropathy in Rare Nerve Disease
A groundbreaking gene editing therapy shows promise in stabilizing neuropathy symptoms and reducing disease markers in hereditary transthyretin amyloidosis, offering hope for long-term disease management.
Researchers from University College London's National Amyloidosis Center have reported promising results from a novel gene editing therapy for hereditary transthyretin amyloidosis with polyneuropathy, a serious and often fatal nerve disorder. The therapy, named nexiguran ziclumeran, involves a single infusion that significantly lowers serum transthyretin (TTR) protein levels. TTR is responsible for amyloid deposits in tissues, which cause nerve and organ damage.
In a multinational Phase I trial involving 36 patients across France, New Zealand, Sweden, and the UK, the treatment resulted in rapid, profound, and sustained reductions in TTR levels — a decrease of approximately 90% at 28 days and over 92% at 24 months. Notably, most patients' neuropathy scores remained stable or improved over the 24-month period, indicating a potential halt or slowdown in disease progression.
Hereditary transthyretin amyloidosis is characterized by the abnormal accumulation of misfolded TTR protein in peripheral nerves, leading to progressive nerve damage. The disease's median survival ranges from six to twelve years after onset, with current available treatments requiring ongoing administration and only partial efficacy.
This study, published in The New England Journal of Medicine, highlights the possible of gene editing to produce durable disease modification. The therapy was generally well-tolerated, with side effects mostly related to infusion reactions, headaches, diarrhea, and some changes in thyroid hormone levels. Serious adverse events included one death due to cardiac amyloidosis.
The findings suggest that a one-time gene editing approach like nexiguran ziclumeran could revolutionize the treatment landscape for this devastating disease, leading to more effective and less burdensome management options. Further research is ongoing to confirm long-term safety and efficacy.
Source: https://medicalxpress.com/news/2025-10-stabilization-neuropathy-scores-gene-therapy.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Innovative Gene-Edited Immune Cells Pave the Way for Universal 'Off-the-Shelf' Cancer Treatments
Scientists have developed a universal, off-the-shelf CAR-T cell therapy using gene editing to enhance immune evasion, promising faster and more accessible cancer treatment options.
Experts Urge Action to Address Conflicts of Interest to Safeguard Public Health
A University of Bath study highlights the urgent need to tackle conflicts of interest with industries harming public health, to ensure effective health policies and sustained healthcare systems.
New Insights into How the Human Brain Categorizes and Stores Visual Memories through Neural Timing
New research uncovers how the human hippocampus categorizes visual memories through precise neural timing, advancing our understanding of memory encoding and opening new avenues for neurorestorative therapies.
Sleep Apnea Raises Risk of Sudden Cardiac Arrest in Children with Epilepsy
Children with epilepsy who also suffer from sleep apnea are at a higher risk of sudden cardiac arrest and heart rhythm problems. A new study emphasizes the importance of early detection and targeted treatment to reduce these risks.